vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与GRIFFON CORP（GFF）财务数据对比。点击上方公司名可切换其他公司
GRIFFON CORP的季度营收约是BIOCRYST PHARMACEUTICALS INC的1.6倍（$649.1M vs $406.6M），BIOCRYST PHARMACEUTICALS INC净利率更高（60.5% vs 9.9%，领先50.6%），BIOCRYST PHARMACEUTICALS INC同比增速更快（209.1% vs 2.6%），BIOCRYST PHARMACEUTICALS INC自由现金流更多（$291.2M vs $99.3M），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（109.4% vs -1.8%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
格里芬公司是总部位于纽约的跨国多元化控股集团，业务覆盖多领域运营，旗下拥有Ames True Temper、ClosetMaid、Clopay建筑产品和CornellCookson四大子公司。该公司1961年起在纽交所公开上市，是标普小盘600指数、标普1500综合指数及罗素2000指数的成分股。
BCRX vs GFF — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $406.6M | $649.1M |
| 净利润 | $245.8M | $64.4M |
| 毛利率 | 97.7% | 41.1% |
| 营业利润率 | 64.0% | 17.5% |
| 净利率 | 60.5% | 9.9% |
| 营收同比 | 209.1% | 2.6% |
| 净利润同比 | 1017.5% | -9.1% |
| 每股收益（稀释后） | $1.13 | $1.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $406.6M | $649.1M | ||
| Q3 25 | $159.4M | $662.2M | ||
| Q2 25 | $163.4M | $613.6M | ||
| Q1 25 | $145.5M | $611.7M | ||
| Q4 24 | $131.5M | $632.4M | ||
| Q3 24 | $117.1M | $659.7M | ||
| Q2 24 | $109.3M | $647.8M | ||
| Q1 24 | $92.8M | $672.9M |
| Q4 25 | $245.8M | $64.4M | ||
| Q3 25 | $12.9M | $43.6M | ||
| Q2 25 | $5.1M | $-120.1M | ||
| Q1 25 | $32.0K | $56.8M | ||
| Q4 24 | $-26.8M | $70.9M | ||
| Q3 24 | $-14.0M | $62.5M | ||
| Q2 24 | $-12.7M | $41.1M | ||
| Q1 24 | $-35.4M | $64.1M |
| Q4 25 | 97.7% | 41.1% | ||
| Q3 25 | 98.6% | 41.7% | ||
| Q2 25 | 98.3% | 43.2% | ||
| Q1 25 | 96.9% | 41.2% | ||
| Q4 24 | 95.4% | 41.8% | ||
| Q3 24 | 97.3% | 39.9% | ||
| Q2 24 | 98.4% | 38.5% | ||
| Q1 24 | 98.6% | 40.2% |
| Q4 25 | 64.0% | 17.5% | ||
| Q3 25 | 18.6% | 18.0% | ||
| Q2 25 | 18.2% | -20.5% | ||
| Q1 25 | 14.6% | 16.5% | ||
| Q4 24 | -3.4% | 17.7% | ||
| Q3 24 | 6.6% | 16.9% | ||
| Q2 24 | 8.0% | 13.8% | ||
| Q1 24 | -15.6% | 16.9% |
| Q4 25 | 60.5% | 9.9% | ||
| Q3 25 | 8.1% | 6.6% | ||
| Q2 25 | 3.1% | -19.6% | ||
| Q1 25 | 0.0% | 9.3% | ||
| Q4 24 | -20.4% | 11.2% | ||
| Q3 24 | -12.0% | 9.5% | ||
| Q2 24 | -11.6% | 6.3% | ||
| Q1 24 | -38.1% | 9.5% |
| Q4 25 | $1.13 | $1.41 | ||
| Q3 25 | $0.06 | $1.04 | ||
| Q2 25 | $0.02 | $-2.65 | ||
| Q1 25 | $0.00 | $1.21 | ||
| Q4 24 | $-0.13 | $1.49 | ||
| Q3 24 | $-0.07 | $1.29 | ||
| Q2 24 | $-0.06 | $0.84 | ||
| Q1 24 | $-0.17 | $1.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.7M | $95.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-119.2M | $108.9M |
| 总资产 | $514.2M | $2.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $274.7M | $95.3M | ||
| Q3 25 | $212.9M | $99.0M | ||
| Q2 25 | $260.0M | $107.3M | ||
| Q1 25 | $295.1M | $127.8M | ||
| Q4 24 | $320.9M | $152.0M | ||
| Q3 24 | $96.8M | $114.4M | ||
| Q2 24 | $78.4M | $133.5M | ||
| Q1 24 | $84.3M | $123.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.6B |
| Q4 25 | $-119.2M | $108.9M | ||
| Q3 25 | $-387.9M | $74.0M | ||
| Q2 25 | $-421.6M | $63.9M | ||
| Q1 25 | $-451.9M | $214.7M | ||
| Q4 24 | $-475.9M | $227.8M | ||
| Q3 24 | $-468.6M | $224.9M | ||
| Q2 24 | $-475.6M | $223.5M | ||
| Q1 24 | $-476.2M | $202.2M |
| Q4 25 | $514.2M | $2.1B | ||
| Q3 25 | $446.4M | $2.1B | ||
| Q2 25 | $457.2M | $2.1B | ||
| Q1 25 | $480.0M | $2.3B | ||
| Q4 24 | $490.4M | $2.3B | ||
| Q3 24 | $491.3M | $2.4B | ||
| Q2 24 | $472.4M | $2.4B | ||
| Q1 24 | $467.9M | $2.4B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 22.71× | ||
| Q1 25 | — | 7.16× | ||
| Q4 24 | — | 6.48× | ||
| Q3 24 | — | 6.78× | ||
| Q2 24 | — | 6.74× | ||
| Q1 24 | — | 7.84× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $292.0M | $107.0M |
| 自由现金流经营现金流 - 资本支出 | $291.2M | $99.3M |
| 自由现金流率自由现金流/营收 | 71.6% | 15.3% |
| 资本支出强度资本支出/营收 | 0.2% | 1.2% |
| 现金转化率经营现金流/净利润 | 1.19× | 1.66× |
| 过去12个月自由现金流最近4个季度 | $344.9M | $278.9M |
8季度趋势，按日历期对齐
| Q4 25 | $292.0M | $107.0M | ||
| Q3 25 | $41.6M | $75.0M | ||
| Q2 25 | $41.3M | $123.1M | ||
| Q1 25 | $-27.5M | $16.5M | ||
| Q4 24 | $-5.2M | $142.9M | ||
| Q3 24 | $8.2M | $72.1M | ||
| Q2 24 | $-1.4M | $122.1M | ||
| Q1 24 | $-53.7M | $39.8M |
| Q4 25 | $291.2M | $99.3M | ||
| Q3 25 | $40.3M | $62.4M | ||
| Q2 25 | $41.1M | $114.4M | ||
| Q1 25 | $-27.7M | $2.8M | ||
| Q4 24 | $-5.9M | $125.5M | ||
| Q3 24 | $8.2M | $51.6M | ||
| Q2 24 | $-1.5M | $107.5M | ||
| Q1 24 | $-53.9M | $20.8M |
| Q4 25 | 71.6% | 15.3% | ||
| Q3 25 | 25.3% | 9.4% | ||
| Q2 25 | 25.2% | 18.6% | ||
| Q1 25 | -19.0% | 0.5% | ||
| Q4 24 | -4.5% | 19.8% | ||
| Q3 24 | 7.0% | 7.8% | ||
| Q2 24 | -1.4% | 16.6% | ||
| Q1 24 | -58.1% | 3.1% |
| Q4 25 | 0.2% | 1.2% | ||
| Q3 25 | 0.8% | 1.9% | ||
| Q2 25 | 0.1% | 1.4% | ||
| Q1 25 | 0.1% | 2.2% | ||
| Q4 24 | 0.5% | 2.8% | ||
| Q3 24 | 0.1% | 3.1% | ||
| Q2 24 | 0.1% | 2.2% | ||
| Q1 24 | 0.3% | 2.8% |
| Q4 25 | 1.19× | 1.66× | ||
| Q3 25 | 3.23× | 1.72× | ||
| Q2 25 | 8.12× | — | ||
| Q1 25 | -859.91× | 0.29× | ||
| Q4 24 | — | 2.02× | ||
| Q3 24 | — | 1.15× | ||
| Q2 24 | — | 2.97× | ||
| Q1 24 | — | 0.62× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
暂无分部数据
GFF
| Consumer And Professional Products | $241.1M | 37% |
| Residential Repairand Remodel | $202.1M | 31% |
| International Excluding North America | $97.8M | 15% |
| Retail | $47.3M | 7% |
| Residential New Construction | $32.5M | 5% |
| Other | $14.2M | 2% |
| Industrial | $14.1M | 2% |
